London · Delayed Price · Currency is GBP · Price in GBX Thalia Therapeutics Company Description
Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom.
The company offers develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines.
It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
The company also engages in the development of N4 101, an orally delivered inflammation inhibitor for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring.
The company has its collaboration with the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde to support the scale-up and characterisation of Nuvec.
The company was formerly known as N4 Pharma Plc and changed its name to Thalia Therapeutics Plc in March 2026.
Thalia Therapeutics Plc was incorporated in 1979 and is based in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1979 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Solomon |
Contact Details
Address: 2 Portman Street London, W1H 6DU United Kingdom | |
| Phone | 44 20 4610 0714 |
| Website | thaliatx.com |
Stock Details
| Ticker Symbol | THAT |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BYW8QM32 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| David Solomon | Chief Executive Officer |